Alkem Laboratories reports higher Q2 revenue but a decline in profit, along with changes in its top management. Across the outlets, the company’s quarterly revenue from operations rises to about ₹4,552 crore, while consolidated net profit falls to the mid-₹600 crore range.
The coverage also points to cost and business-structure pressures. One report highlights weaker profitability as expenses increase faster than revenue and notes a significantly higher tax expense burden. Another outlet attributes biotech weakness to the “lumpy” nature of its CDMO (contract development and manufacturing organisation) business, alongside biotech sales falling year-on-year.
In addition to the financial figures, one outlet emphasises corporate governance by reporting that Alkem ropes in Gopal Kothari as CFO. While all sources align on the broad outcome—upside in revenue with profit pressure—each frames the story differently, focusing either on operational drivers (biotech/CDMO), profitability metrics and tax effects, or management changes.
